Shares of Verona Pharma plc (NASDAQ:VRNA), a clinical-stage biopharmaceutical company focused on respiratory disease treatments, plummeted 5.95% in the pre-market trading session on Friday.
The stock's decline comes despite an analysis article suggesting that Verona Pharma is expected to break even in 2025 and become profitable in 2026, according to consensus estimates from industry analysts covering the company. The article highlights that analysts forecast an average annual growth rate of 59% for Verona Pharma to achieve profitability, which is considered optimistic.
However, the article also notes that Verona Pharma has a relatively high level of debt, with debt exceeding 92% of its equity. This high debt obligation increases the risk for investors in the loss-making company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.